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Heart failure (HF) is defined as 
a clinical syndrome in which typical 
symptoms such as breathlessness, 
fatigue and others accompanied by 
signs of pulmonary and/or peripheral 
congestion resulting from structural 
and/or a functional cardiac abnorma-
lity leading to reduced cardiac output 
and/or elevated intracardiac pressures 
at rest or during exertion [1]. Clinical presenta-
tion of HF should be confirmed by transthoracic 
echocardiography (TTE) which reveals cardiac 
morphology, function and allows the calculation of 
ejection fraction of the left ventricle (LVEF). Low 
ejection fraction (EF) corroborates HF diagnosis, 
nevertheless in a substantial number of patients 
with obvious clinical HF manifestation LVEF 
remains within the normal range (≥ 50%). The 
latter group constitutes a separate category of HF 
patients — with preserved ejection fraction of the 
left ventricle (HFpEF) which differs in many as-
pects from those with reduced EF (HFrEF). These 
differences mainly include risk factors, comorbidi-
ties, patient demographics, diagnostic algorithm 
and evidence-based treatment.
Heart failure with preserved ejection fraction 
of the left ventricle has become a preponderant 
form of HF in western countries accounting for 
> 70% amongst patients > 65 years and is con-
stantly growing with every decade of life and the gap 
between HFpEF and HFrEF is getting wider [2]. 
This is caused by growing number of obese, dia-
betic individuals, with metabolic syndrome living 
a sedentary life who are at risk of a progression 
to symptomatic HFpEF if left untreated. The dif-
ference in LVEF which defines both 
groups results from an entirely distinct 
cardiac pathophysiology leading to 
a decrease in overall ventricular per-
formance which is described by left 
ventricular (LV) pressure/volume 
relationship. If dominant functional 
abnormality in HFrEF is diminished 
LV contractility defined by a decrease 
in the slope of the end-systolic pres-
sure-volume relationship (systolic 
elastance), the HFpEF exhibits in-
crease in LV diastolic stiffness causing an upward 
and leftward shift of the diastolic pressure-volume 
relationship [3]. In some individuals this may occur 
only on exertion. Invasive evaluation of the filling 
pressures remains the gold standard of diagnosing 
HFpEF and currently is the only method which un-
equivocally proves or refutes its pathophysiology. 
For years HF was diagnosed on the grounds 
of clinical findings known as the Framingham 
criteria which suffer from poor sensitivity [2]. In 
particular, well compensated patients with HFpEF 
who develop symptoms only by exertion may go 
unrecognized. Although invasive assessment may 
confirm increased diastolic filling pressures during 
exercise this method cannot be applied as widely 
as required for obvious reasons. Alternatively, 
echocardiography is widely utilized to discover LV 
diastolic dysfunction. Elevation in the E/e’ indicat-
ing higher LV filling pressures as well as increased 
estimated systolic pulmonary artery pressure rep-
resents the most robust indicators of HFpEF [4]. 
TTE also uncovers other structural (LV hyper-
trophy, higher left atrial volume) and functional 
(RVFAC, TAPSE) abnormalities associated with 
HFpEF. Recently, speckle tracking echocardio-
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subtly diminished ventricular systolic function in 
a subclinical phase of the disease when EF remains 
normal. Most of TTE parameters are specific but 
not sensitive enough to rule out the absence of 
HFpEF. American Society of Echocardiography/ 
/European Association of Cardiovascular Imaging 
recommendations provide meticulous algorithms 
for studying and interpreting LV diastolic perfor-
mance both in patients with reduced and preserved 
EF. Of utmost importance is ability of echocardio-
graphy to rule out secondary HFpEF due to val-
vular disease, pericarditis and other conditions 
requiring specific diagnostic and therapeutic strate-
gies. Further, TTE enables noninvasive evaluation 
during exercise which may unmask diastolic dys-
function in case of normal parameters at rest [5].
Owing to the difficulties and doubts concerning 
the diagnosis of the HFpEF two comprehensive 
diagnostic scores integrating clinical and echo-
cardiographic variables were recently proposed in 
order to appreciate the risk of HFpEF. For patients 
with unexplained dyspnea Reddy et al. [4] devel-
oped H2FPEF composite score which assesses 
the probability of HFpEF. Importantly, HFpEF as 
established by H2FPEF was verified by means of 
invasive hemodynamic exercise testing in every 
patient [4]. Utilization of the score enables the 
Bayesian approach in which only patients with 
intermediate pre-test probability are referred for 
a definitive test including exercise testing. 
A similar score was proposed as a consensus expert 
statement (HFA-PEFF) which, thus far, has not 
been verified by means of invasive tests [6]. The 
latter score adds a concentration of N-terminal-pro- 
-B-type natriuretic peptide, more echocardio-
graphic morphological and functional parameters as 
well as exercise echocardiography. An intermediate 
probability is an indication for subsequent hemo-
dynamic exercise testing.
Despite diagnostic uncertainties, many symp-
tomatic patients worldwide are diagnosed as having 
HFpEF and are subsequently treated. However, 
contrary to HFrEF, large-scale clinical trials did 
not provide firm clues concerning treatment de-
spite testing many hypotheses, drugs from vari-
ous classes and non-pharmacological strategies. 
Considering the variety of etiologies and patho-
physiologies, it seems to be justified to categorize 
HFpEF patients into more homogeneous pheno-
types which may lead to better characterization 
of the entire HFpEF cohort. Various features and 
parameters modifying such a phenotype include 
comorbidities, cardiac and pulmonary vascular 
function, hemodynamics, extracardiac structure, 
function and biomarkers [2]. Obokata et al. [7] 
proposed obese, ischemic, and cardiometabolic 
phenotypes as three major categories of HFpEF 
pointing to essential differences among them and 
their preferred therapeutic options. It is conceiv-
able that one therapeutic strategy may turn out 
valuable only in a given well-defined HFpEF phe-
notype and not in others. However, there are still 
many more issues to be addressed with regard to 
pathophysiology, definition, diagnostic algorithms 
and therapies since HFpEF encompasses various 
hemodynamic and cellular mechanisms [8]. With 
respect to noninvasive assessment of HFpEF, di-
astolic stress echocardiography remains the only 
tool which is capable of recognizing patients with 
symptoms solely with exercise. Nonetheless, a lot 
of effort has to be made to refine and standardize 
its methodology. On the other hand, simplification 
of a diagnostic approach should be sought for such 
as combination of simple TTE parameters and 
biomarkers as well as selection of simple highly 
reproducible parameters used for community based 
epidemiological studies and screening performed 
in populations at risk [9, 10]. Another important 
diagnostic issue concerns the potential role for 
other noninvasive imaging modalities in diagnosing 
HFpEF. From a therapeutic standpoint the question 
remains unanswered — which pathophysiological 
pathways should be modified in order to slow down 
or to stop the disease. Is there one leading pathway 
eventually resulting in HFpEF, or is it a mixture of 
interacting mechanisms?
Heart failure with preserved ejection fraction 
of the left ventricle became a dominant form of HF 
worldwide and is associated with high morbidity 
and mortality. Despite enormous scientific effort 
there are still many clinical doubts regarding this 
clinical syndrome. Therefore, one has to appreci-
ate an excellent review on this topic prepared by 
Club 30 of the Polish Cardiac Society published in 
current issue of “Cardiology Journal” [11]. Indeed, 
a guide to the guidelines is still needed while deal-
ing with HFpEF and its dilemmas.
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